Table 1. Patient characteristics and mucinous histology.
| |
|
|
|
P-values |
|||
|---|---|---|---|---|---|---|---|
| Total (N=521) | NMA (N=453) | AIM (N=41) | MAC (N=27) | AIM vs NMA | MAC vs NMA | AIM vs MAC | |
|
Age | |||||||
| Median (range) | 60 (25–81) | 60 (35–76) | 62 (25–81) | 56 (30–81) | |||
| ⩾65 years |
155 (29.8%) |
128 (28.3%) |
19 (46.3%) |
8 (29.6%) |
0.015 |
0.88 |
0.17 |
|
Sex | |||||||
| Male | 312 (59.9%) | 283 (62.5%) | 13 (31.7%) | 16 (59.3%) | <0.001 | 0.74 | 0.025 |
| Female |
209 (40.1%) |
170 (37.5%) |
28 (68.3%) |
11 (40.7%) |
|
|
|
|
Location | |||||||
| Proximal | 181 (34.7%) | 140 (30.9%) | 25 (61.0%) | 16 (59.3%) | <0.001 | 0.002 | 0.89 |
| Distal |
340 (65.3%) |
313 (69.1%) |
16 (39.0%) |
11 (40.7%) |
|
|
|
|
Stage | |||||||
| II | 78 (15.0%) | 67 (14.8%) | 7 (17.1%) | 4 (14.8%) | 0.70 | 1.0 | 1.0 |
| III |
443 (85.0%) |
386 (85.2%) |
34 (82.9%) |
23 (85.2%) |
|
|
|
|
T stage | |||||||
| T1–3 | 445 (85.4%) | 394 (87.0%) | 35 (85.4%) | 16 (59.3%) | 0.77 | <0.001 | 0.015 |
| T4 |
76 (14.6%) |
59 (13.0%) |
6 (14.6%) |
11 (40.7%) |
|
|
|
|
N stage | |||||||
| N0–1 | 378 (72.6%) | 332 (73.3%) | 29 (70.7%) | 17 (63.0%) | 0.72 | 0.24 | 0.50 |
| N2 |
143 (27.4%) |
121 (26.7%) |
12 (29.3%) |
10 (37.0%) |
|
|
|
|
Angiolymphatic invasion | |||||||
| Present | 223 (42.8%) | 205 (45.3%) | 12 (29.3%) | 6 (22.2%) | 0.048 | 0.019 | 0.52 |
| Absent |
298 (57.2%) |
248 (54.7%) |
29 (70.7%) |
21 (77.8%) |
|
|
|
|
Venous invasion | |||||||
| Present | 57 (10.9%) | 54 (11.9%) | 1 (2.4%) | 2 (7.4%) | 0.070 | 0.76 | 0.56 |
| Absent |
464 (89.1%) |
399 (88.1%) |
40 (97.6%) |
25 (92.6%) |
|
|
|
|
Perineural invasion | |||||||
| Present | 120 (23.0%) | 112 (24.7%) | 5 (12.2%) | 3 (11.1%) | 0.084 | 0.16 | 1.00 |
| Absent |
401 (77.0%) |
341 (75.3%) |
36 (87.8%) |
24 (88.9%) |
|
|
|
|
Microsatellite status | |||||||
| MSS+MSI-L | 483 (93.2%) | 425 (94.4%) | 35 (85.4%) | 23 (85.2%) | 0.022 | 0.073 | 1.00 |
| MSI-H | 35 (6.8%) | 25 (5.6%) | 6 (14.6%) | 4 (14.8%) | |||
Abbreviations: AIM=adenocarcinoma with intermediate mucinous component; MAC=mucinous adenocarcinoma; MSI-H=high microsatellite instability; MSI-L=low microsatellite instability; MSS=microsatellite stable; NMA=non-mucinous adenocarcinoma.